Log in

NASDAQ:DERM - Dermira Stock Price, Forecast & News

$18.75
0.00 (0.00 %)
(As of 02/24/2020 06:06 AM ET)
Today's Range
$18.75
Now: $18.75
$18.75
50-Day Range
$14.65
MA: $18.45
$19.19
52-Week Range
$5.25
Now: $18.75
$19.48
VolumeN/A
Average Volume1.24 million shs
Market Capitalization$1.02 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.56
Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older. It also develops lebrikizumab, a novel injectable humanized monoclonal antibody targeting interleukin 13 that is in Phase IIb clinical trial for the treatment of moderate-to-severe atopic dermatitis; and early-stage research and development programs in other areas of dermatology. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DERM
CUSIPN/A
Phone650-421-7200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$42.34 million
Book Value($0.21) per share

Profitability

Net Income$-221,540,000.00
Net Margins-256.08%

Miscellaneous

Employees333
Market Cap$1.02 billion
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive DERM News and Ratings via Email

Sign-up to receive the latest news and ratings for DERM and its competitors with MarketBeat's FREE daily newsletter.


Dermira (NASDAQ:DERM) Frequently Asked Questions

What is Dermira's stock symbol?

Dermira trades on the NASDAQ under the ticker symbol "DERM."

How were Dermira's earnings last quarter?

Dermira Inc (NASDAQ:DERM) announced its quarterly earnings data on Tuesday, November, 5th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.40) by $0.34. The biopharmaceutical company had revenue of $11.53 million for the quarter, compared to analysts' expectations of $11.07 million. Dermira had a negative return on equity of 583.07% and a negative net margin of 256.08%. View Dermira's Earnings History.

When is Dermira's next earnings date?

Dermira is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Dermira.

What price target have analysts set for DERM?

9 equities research analysts have issued 1-year target prices for Dermira's stock. Their forecasts range from $14.00 to $25.00. On average, they expect Dermira's stock price to reach $18.79 in the next twelve months. This suggests a possible upside of 0.2% from the stock's current price. View Analyst Price Targets for Dermira.

What is the consensus analysts' recommendation for Dermira?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dermira in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dermira.

What are Wall Street analysts saying about Dermira stock?

Here are some recent quotes from research analysts about Dermira stock:
  • 1. According to Zacks Investment Research, "Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. " (1/14/2020)
  • 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We maintain our Buy rating and $7 price target. The STING program currently contributes approximately 53% to our valuation (no contribution from early stage Lilly program currently) and the APRIL program approximately 43%, with the remainder coming from the anti-CD27 program being developed by Merck (MRK; not rated). Our target is based on our clinical net present value (NPV) model. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile." (5/8/2019)
  • 3. Cantor Fitzgerald analysts commented, "DERM is a leading dermatology company with commercial and pipeline advancements that could drive upwards earnings revisions and the stock higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $25." (5/3/2019)

Has Dermira been receiving favorable news coverage?

News stories about DERM stock have been trending very negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Dermira earned a news impact score of -3.0 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Dermira.

Are investors shorting Dermira?

Dermira saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 5,610,000 shares, a drop of 17.5% from the January 15th total of 6,800,000 shares. Based on an average daily trading volume, of 2,400,000 shares, the short-interest ratio is currently 2.3 days. Currently, 12.4% of the shares of the stock are short sold. View Dermira's Current Options Chain.

Who are some of Dermira's key competitors?

What other stocks do shareholders of Dermira own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dermira investors own include Gilead Sciences (GILD), Micron Technology (MU), Advanced Micro Devices (AMD), AT&T (T), Exelixis (EXEL), Novavax (NVAX), TG Therapeutics (TGTX), AbbVie (ABBV), Bristol-Myers Squibb (BMY) and ImmunoGen (IMGN).

Who are Dermira's key executives?

Dermira's management team includes the folowing people:
  • Mr. Thomas G. Wiggans, Co-Founder, CEO & Chairman (Age 67)
  • Dr. Eugene Andrew Bauer, Co-Founder, Chief Medical Officer & Director (Age 77)
  • Mr. Andrew L. Guggenhime, Chief Financial Officer (Age 51)
  • Ms. Lori Lyons-Williams, Chief Commercial Officer (Age 42)
  • Mr. Christopher M. Griffith, Co-Founder and Chief Bus. & Strategy Officer (Age 43)

Who are Dermira's major shareholders?

Dermira's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Fred Alger Management LLC (5.60%), Oracle Investment Management Inc. (4.64%), Bank of America Corp DE (3.70%), State Street Corp (1.80%), Broadfin Capital LLC (1.64%) and Earnest Partners LLC (1.48%). Company insiders that own Dermira stock include David E Cohen, Eagle Acquisition Corp Bald, Eugene A Bauer, Matthew K Fust and Thomas G Wiggans. View Institutional Ownership Trends for Dermira.

Which institutional investors are selling Dermira stock?

DERM stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Credit Suisse AG, Citigroup Inc., Fred Alger Management LLC, Renaissance Technologies LLC, Sofinnova Investments Inc., Panagora Asset Management Inc. and Partner Investment Management L.P.. Company insiders that have sold Dermira company stock in the last year include Eugene A Bauer and Matthew K Fust. View Insider Buying and Selling for Dermira.

Which institutional investors are buying Dermira stock?

DERM stock was bought by a variety of institutional investors in the last quarter, including Oracle Investment Management Inc., Jacobs Levy Equity Management Inc., Broadfin Capital LLC, Rhenman & Partners Asset Management AB, Candriam Luxembourg S.C.A., Earnest Partners LLC, Alliancebernstein L.P. and EAM Global Investors LLC. Company insiders that have bought Dermira stock in the last two years include Eagle Acquisition Corp Bald and Thomas G Wiggans. View Insider Buying and Selling for Dermira.

How do I buy shares of Dermira?

Shares of DERM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Dermira's stock price today?

One share of DERM stock can currently be purchased for approximately $18.75.

How big of a company is Dermira?

Dermira has a market capitalization of $1.02 billion and generates $42.34 million in revenue each year. The biopharmaceutical company earns $-221,540,000.00 in net income (profit) each year or ($5.24) on an earnings per share basis. Dermira employs 333 workers across the globe.View Additional Information About Dermira.

What is Dermira's official website?

The official website for Dermira is http://www.dermira.com/.

How can I contact Dermira?

Dermira's mailing address is 275 Middlefield Road Suite150, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at 650-421-7200 or via email at [email protected]


MarketBeat Community Rating for Dermira (NASDAQ DERM)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  337 (Vote Outperform)
Underperform Votes:  306 (Vote Underperform)
Total Votes:  643
MarketBeat's community ratings are surveys of what our community members think about Dermira and other stocks. Vote "Outperform" if you believe DERM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DERM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel